These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
323 related articles for article (PubMed ID: 25023650)
1. Physician variation in management of low-risk prostate cancer: a population-based cohort study. Hoffman KE; Niu J; Shen Y; Jiang J; Davis JW; Kim J; Kuban DA; Perkins GH; Shah JB; Smith GL; Volk RJ; Buchholz TA; Giordano SH; Smith BD JAMA Intern Med; 2014 Sep; 174(9):1450-9. PubMed ID: 25023650 [TBL] [Abstract][Full Text] [Related]
2. Urologist-Level Correlation in the Use of Observation for Low- and High-Risk Prostate Cancer. Tyson MD; Graves AJ; O'Neil B; Barocas DA; Chang SS; Penson DF; Resnick MJ JAMA Surg; 2017 Jan; 152(1):27-34. PubMed ID: 27653425 [TBL] [Abstract][Full Text] [Related]
3. Physician visits prior to treatment for clinically localized prostate cancer. Jang TL; Bekelman JE; Liu Y; Bach PB; Basch EM; Elkin EB; Zelefsky MJ; Scardino PT; Begg CB; Schrag D Arch Intern Med; 2010 Mar; 170(5):440-50. PubMed ID: 20212180 [TBL] [Abstract][Full Text] [Related]
4. Regional Variation in Active Surveillance for Low-Risk Prostate Cancer in the US. Washington SL; Jeong CW; Lonergan PE; Herlemann A; Gomez SL; Carroll PR; Cooperberg MR JAMA Netw Open; 2020 Dec; 3(12):e2031349. PubMed ID: 33369661 [TBL] [Abstract][Full Text] [Related]
5. Variation in the use of active surveillance for low-risk prostate cancer. Löppenberg B; Friedlander DF; Krasnova A; Tam A; Leow JJ; Nguyen PL; Barry H; Lipsitz SR; Menon M; Abdollah F; Sammon JD; Sun M; Choueiri TK; Kibel AS; Trinh QD Cancer; 2018 Jan; 124(1):55-64. PubMed ID: 28902401 [TBL] [Abstract][Full Text] [Related]
6. Factors associated with initial treatment and survival for clinically localized prostate cancer: results from the CDC-NPCR Patterns of Care Study (PoC1). Schymura MJ; Kahn AR; German RR; Hsieh MC; Cress RD; Finch JL; Fulton JP; Shen T; Stuckart E BMC Cancer; 2010 Apr; 10():152. PubMed ID: 20403178 [TBL] [Abstract][Full Text] [Related]
7. Association between urologist characteristics and radiation oncologist consultation for patients with locoregional prostate cancer. Quek RG; Ward KC; Master VA; Lin CC; Portier KM; Virgo KS; Lipscomb J J Natl Compr Canc Netw; 2015 Mar; 13(3):303-9. PubMed ID: 25736007 [TBL] [Abstract][Full Text] [Related]
8. Population-Based Assessment of Determining Treatments for Prostate Cancer. Chamie K; Williams SB; Hu JC JAMA Oncol; 2015 Apr; 1(1):60-7. PubMed ID: 26182305 [TBL] [Abstract][Full Text] [Related]
9. Comparison of recommendations by urologists and radiation oncologists for treatment of clinically localized prostate cancer. Fowler FJ; McNaughton Collins M; Albertsen PC; Zietman A; Elliott DB; Barry MJ JAMA; 2000 Jun; 283(24):3217-22. PubMed ID: 10866869 [TBL] [Abstract][Full Text] [Related]
10. Recommendations of Active Surveillance for Intermediate-risk Prostate Cancer: Results from a National Survey of Radiation Oncologists and Urologists. Kim SP; Shah ND; Meropol NJ; Tilburt JC; Nguyen PL; Yu JB; Abouassaly R; Kim A; Gross CP Eur Urol Oncol; 2019 Mar; 2(2):189-195. PubMed ID: 31017095 [TBL] [Abstract][Full Text] [Related]
11. Management of localised prostate cancer: watchful waiting, surgery or radiation therapy, depending on the natural course, which is often relatively slow. Prescrire Int; 2012 Oct; 21(131):242-8. PubMed ID: 23185849 [TBL] [Abstract][Full Text] [Related]
12. Urologists' referral and radiation oncologists' treatment patterns regarding high-risk prostate cancer patients receiving radiotherapy within 6 months after radical prostatectomy: A prospective cohort analysis. Egger S; Smith DP; Brown BB; Kneebone AB; Dominello A; Brooks AJ; Young J; Xhilaga M; Haines M; O'Connell DL J Med Imaging Radiat Oncol; 2020 Feb; 64(1):134-143. PubMed ID: 31793211 [TBL] [Abstract][Full Text] [Related]
14. Physician social networks and variation in prostate cancer treatment in three cities. Pollack CE; Weissman G; Bekelman J; Liao K; Armstrong K Health Serv Res; 2012 Feb; 47(1 Pt 2):380-403. PubMed ID: 22092259 [TBL] [Abstract][Full Text] [Related]
15. Association of reimbursement policy and urologists' characteristics with the use of medical androgen deprivation therapy for clinically localized prostate cancer. Quek RG; Master VA; Portier KM; Ward KC; Lin CC; Virgo KS; Lipscomb J Urol Oncol; 2014 Aug; 32(6):748-60. PubMed ID: 24840868 [TBL] [Abstract][Full Text] [Related]
16. Variation in use of active surveillance among men undergoing expectant treatment for early stage prostate cancer. Filson CP; Schroeck FR; Ye Z; Wei JT; Hollenbeck BK; Miller DC J Urol; 2014 Jul; 192(1):75-80. PubMed ID: 24518783 [TBL] [Abstract][Full Text] [Related]
17. United States radiation oncologists' and urologists' opinions about screening and treatment of prostate cancer vary by region. McNaughton Collins M; Barry MJ; Zietman A; Albertsen PC; Talcott JA; Walker Corkery E; Elliott DB; Fowler FJ Urology; 2002 Oct; 60(4):628-33. PubMed ID: 12385923 [TBL] [Abstract][Full Text] [Related]
18. Expectant management of veterans with early-stage prostate cancer. Filson CP; Shelton JB; Tan HJ; Kwan L; Skolarus TA; Saigal CS; Litwin MS Cancer; 2016 Feb; 122(4):626-33. PubMed ID: 26540451 [TBL] [Abstract][Full Text] [Related]
19. Race/ethnicity and the intensity of medical monitoring under 'watchful waiting' for prostate cancer. Shavers VL; Brown M; Klabunde CN; Potosky AL; Davis W; Moul J; Fahey A Med Care; 2004 Mar; 42(3):239-50. PubMed ID: 15076823 [TBL] [Abstract][Full Text] [Related]
20. Racial disparities in changing to a high-volume urologist among men with localized prostate cancer. Pollack CE; Bekelman JE; Epstein AJ; Liao K; Wong YN; Armstrong K Med Care; 2011 Nov; 49(11):999-1006. PubMed ID: 22005606 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]